Dacarbazine

Known as: Dakarbazin, Dacarbazinum, Dacarbazine - DTIC 
A drug that is used to treat Hodgkin lymphoma and malignant melanoma and is being studied in the treatment of other types of cancer. It attaches to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1939-2018
010020030019392017

Related topics

Related topics

41 relations
ABVD protocolBlood Coagulation DisordersCOPDAC RegimenCYVADIC protocol
(More)

Broader (1)

Antineoplastic Agents, Alkylating

Narrower (11)

BELD protocolBiocarbazineDAV protocolDTIC-Dome
(More)

Related mentions per year

Related mentions per year

1936-2019
19401960198020002020
Dacarbazine
Blood Coagulation Disorders
melanoma
Neuroblastoma
Rhabdomyosarcoma
temozolomide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Nivolumab in previously untreated melanoma without BRAF mutation.
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
BACKGROUND Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Improved survival with MEK inhibition in BRAF-mutated melanoma.
BACKGROUND Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
PURPOSE Chemotherapy resistance in melanoma has been linked to antiapoptotic effects mediated by Bcl-2 protein. We evaluated… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
PURPOSE To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
PURPOSE Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic…
PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival, and toxicity in patients with… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl… (More)
Is this relevant?
Highly Cited
1978
Highly Cited
1978
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.
A human leukemic cell line (designated HL-60) has recently been established from the peripheral blood leukocytes of a patient… (More)
Is this relevant?